Additional outpatient therapies which are readily accessible will be essential to reduce COVID-19 illness progression in high risk individuals. Especially as the virus continues to mutate with greater transmissibility despite increased global vaccination.
Use of NONS in patients recently infected with SARS-CoV-2 accelerates nasal virus clearance.
Funding provided by Glenmark Pharmaceuticals Limited. Study medication provided by SaNOtize.
Leave a reply